

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

Anti-Survivin-PE, human

RRID:AB_2653606

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-106-741, RRID:AB_2653606

Antibody Information

URL: http://antibodyregistry.org/AB_2653606

Proper Citation: Miltenyi Biotec Cat# 130-106-741, RRID:AB_2653606

Target Antigen: Survivin

Host Organism: human

Clonality: monoclonal

Comments: Discontinued: 4-2018; Target Distribution breast cancer cells, lung cancer cells, prostate cancer cells, bladder, colon, other; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-119-139. (RRID:AB_2733894).

Antibody Name: Anti-Survivin-PE, human

Description: This monoclonal targets Survivin

Target Organism: human

Clone ID: REA459

Antibody ID: AB_2653606

Vendor: Miltenyi Biotec

Catalog Number: 130-106-741

Record Creation Time: 20231110T034447+0000

Record Last Update: 20260829T084317+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Survivin-PE, human.

Warning: Discontinued: 2021

Discontinued: 4-2018; Target Distribution breast cancer cells, lung cancer cells, prostate cancer cells, bladder, colon, other; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-119-139. (RRID:AB_2733894).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Herati RS, et al. (2021) Vaccine-induced ICOS+CD38+ circulating Tfh are sensitive biosensors of age-related changes in inflammatory pathways. Cell reports. Medicine, 2(5), 100262.